The FDA granted 510(k) clearance for LivaNova’s Memo 4D semi-rigid mitral annuloplasty ring and confirmed the device’s first implantation.

The Memo 4D now offers a broader range of ring sizes from 24 to 42mm, allowing a new patient population to be treated for mitral regurgitation.

The device provides a chordal guide to speed up procedure times, and its improved ring design can reduce the risk of systolic anterior motion.